Illumina, Inc. (NASDAQ:ILMN) Holdings Increased by CVA Family Office LLC

CVA Family Office LLC grew its position in shares of Illumina, Inc. (NASDAQ:ILMNGet Rating) by 53.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 300 shares of the life sciences company’s stock after purchasing an additional 105 shares during the quarter. CVA Family Office LLC’s holdings in Illumina were worth $57,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Private Trust Co. NA acquired a new stake in shares of Illumina during the second quarter worth approximately $25,000. Zions Bancorporation N.A. boosted its position in Illumina by 97.6% during the third quarter. Zions Bancorporation N.A. now owns 164 shares of the life sciences company’s stock valued at $31,000 after purchasing an additional 81 shares during the last quarter. Guardian Wealth Advisors LLC purchased a new position in Illumina in the third quarter valued at about $33,000. Massmutual Trust Co. FSB ADV increased its position in Illumina by 50.0% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 183 shares of the life sciences company’s stock worth $35,000 after purchasing an additional 61 shares during the last quarter. Finally, SOA Wealth Advisors LLC. lifted its holdings in shares of Illumina by 282.7% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 199 shares of the life sciences company’s stock valued at $37,000 after buying an additional 147 shares during the last quarter. 87.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Illumina news, SVP Aimee L. Hoyt sold 871 shares of the business’s stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $205.57, for a total value of $179,051.47. Following the sale, the senior vice president now owns 2,796 shares in the company, valued at approximately $574,773.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, SVP Aimee L. Hoyt sold 871 shares of the stock in a transaction on Monday, January 9th. The shares were sold at an average price of $205.57, for a total transaction of $179,051.47. Following the completion of the transaction, the senior vice president now owns 2,796 shares in the company, valued at $574,773.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Susan H. Tousi sold 500 shares of Illumina stock in a transaction on Monday, February 6th. The shares were sold at an average price of $211.57, for a total transaction of $105,785.00. Following the completion of the sale, the senior vice president now owns 38,276 shares in the company, valued at $8,098,053.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,186 shares of company stock worth $2,255,837. 0.13% of the stock is owned by corporate insiders.

Illumina Stock Performance

Shares of ILMN stock opened at $224.95 on Friday. The company has a market capitalization of $35.54 billion, a P/E ratio of -8.03, a price-to-earnings-growth ratio of 8.27 and a beta of 1.15. Illumina, Inc. has a 52 week low of $173.45 and a 52 week high of $371.16. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.08 and a current ratio of 1.28. The company’s 50 day moving average price is $208.40 and its two-hundred day moving average price is $208.60.

Illumina (NASDAQ:ILMNGet Rating) last issued its quarterly earnings data on Tuesday, February 7th. The life sciences company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.11). The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a positive return on equity of 3.79% and a negative net margin of 96.12%. The company’s revenue was down 9.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.75 earnings per share. On average, analysts expect that Illumina, Inc. will post 1.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of a number of analyst reports. Canaccord Genuity Group reduced their target price on shares of Illumina from $330.00 to $300.00 and set a “buy” rating for the company in a research note on Tuesday, January 17th. UBS Group reduced their price target on Illumina from $255.00 to $240.00 and set a “neutral” rating for the company in a research report on Tuesday, February 14th. Stifel Nicolaus lowered their price objective on Illumina from $285.00 to $235.00 in a report on Wednesday, February 8th. Citigroup lowered shares of Illumina from a “neutral” rating to a “sell” rating and lowered their target price for the company from $200.00 to $180.00 in a research note on Monday, December 12th. Finally, OTR Global raised shares of Illumina from a “mixed” rating to a “positive” rating in a research report on Tuesday, December 20th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Illumina currently has an average rating of “Hold” and a consensus target price of $249.40.

Illumina Profile

(Get Rating)

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.

Featured Stories

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.